ATIP · Ati Physical Therapy, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $753.06M | $699.02M | $635.67M | $592.25M | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $99.73M | $118.73M | $114.72M | $104.32M | - |
| Total Operating Expenses | $649.59M | $602.21M | $574.42M | $488.85M | - |
| D&A | $33.24M | $37.41M | $40.59M | $39.70M | - |
| Operating Income | $2.28M | ($27.52M) | ($539.73M) | ($913.0K) | - |
| Interest Expense | - | - | - | - | - |
| Income Tax | $1.45M | $2.57M | ($48.53M) | $2.06M | - |
| Net Income | ($58.30M) | ($69.80M) | ($492.38M) | ($5.37M) | - |
| EPS - Basic | ($19.46) | ($31.93) | ($2.51) | ($0.04) | - |
| EPS - Diluted | ($19.46) | ($31.93) | ($2.51) | ($0.04) | - |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | $39.08M | $36.80M | $83.14M | $48.62M | $1.31M |
| Accounts Receivable | $101.97M | $88.51M | $80.67M | $82.45M | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $18.20M | $14.70M | $12.56M | $15.15M | - |
| Current Assets | $157.88M | $168.64M | $194.13M | $143.58M | $1.66M |
| Total Assets | $958.12M | $1.00B | $1.08B | $1.56B | $346.68M |
| Current Liabilities | $141.16M | $156.45M | $116.52M | $137.33M | $1.69M |
| Long-term Debt | - | - | $531.60M | $543.80M | - |
| Total Liabilities | $883.29M | $878.74M | $890.20M | $1.05B | $13.76M |
| Stockholders' Equity | ($176.34M) | ($101.00M) | $43.96M | $504.42M | $5.00M |
| Retained Earnings | ($1.47B) | ($1.41B) | ($1.34B) | ($847.13M) | ($1.59M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($19.17M) | ($12.37M) | ($65.51M) | $138.60M | - |
| Investing Cash Flow | ($14.25M) | ($17.37M) | ($28.05M) | ($21.81M) | - |
| Financing Cash Flow | $35.70M | ($16.61M) | $128.08M | ($12.97M) | - |
| CapEx | $14.85M | $17.32M | $28.15M | $21.89M | - |
| Free Cash Flow | ($34.02M) | ($29.69M) | ($93.66M) | $116.72M | - |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | 0.3% | -3.9% | -84.9% | -0.2% | - |
| EBITDA margin | 4.7% | 1.4% | -78.5% | 6.5% | - |
| Net margin | -7.7% | -10.0% | -77.5% | -0.9% | - |
| Free cash flow margin | -4.5% | -4.2% | -14.7% | 19.7% | - |
| FCF / Net income | 0.58 | 0.43 | 0.19 | -21.73 | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 13.2% | 17.0% | 18.0% | 17.6% | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -6.1% | -7.0% | -45.6% | -0.3% | - |
| Return on equity | 33.1% | 69.1% | -1120.1% | -1.1% | - |
| Return on invested capital | - | - | -74.1% | -0.1% | - |
| Liquidity | |||||
| Current ratio | 1.12 | 1.08 | 1.67 | 1.05 | 0.98 |
| Quick ratio | 1.12 | 1.08 | 1.67 | 1.05 | 0.98 |
| Cash ratio | 0.28 | 0.24 | 0.71 | 0.35 | 0.78 |
| Leverage | |||||
| Debt / Equity | - | - | 12.09 | 1.08 | - |
| Debt / Assets | - | - | 0.49 | 0.35 | - |
| Debt / EBITDA | - | - | - | 14.02 | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | -5.43 | -9.93 | 24.55 | 3.10 | 69.34 |
| Liabilities / Assets | 0.92 | 0.88 | 0.83 | 0.67 | 0.04 |
| Efficiency | |||||
| Asset turnover | 0.79 | 0.70 | 0.59 | 0.38 | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 49d | 46d | 46d | 51d | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 7.7% | 10.0% | 7.3% | - | - |
| Revenue CAGR (3y) | 8.3% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | - | 94.9% | -59016.5% | - | - |
| Net income growth (YoY) | 16.5% | 85.8% | -9067.4% | - | - |
| EPS growth (YoY) | 39.1% | -1172.1% | -6175.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -14.6% | 68.3% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -74.6% | - | -91.3% | 9988.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$816.17M totalHealth Care Patient Service$689.96M · 84.5%
Product And Service Other$63.10M · 7.7%
ATIWorksite Solutions$36.64M · 4.5%
Management Service Agreements$15.32M · 1.9%
Products And Services Sports Medicine And Other Miscellaneous Revenue$11.15M · 1.4%
Stability scores
Altman Z′
FY 2024 · bankruptcy risk
-0.58
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2024 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Nursing & Personal Care Facilities
Comparing ATI Physical Therapy against the 5 most active filers in the same SIC group.